XNCRXencor, Inc.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat pat…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit Xencor, Inc. has reported its second-quarter 2026 results, with net loss improving to US$21.73 million versus US$30.83 million a year earlier, while basic and diluted loss per share from continuing operations narrowed to US$0.29 from US$0.41. Over the first half of 2026, however, Xencor’s net loss widened to US$150.65 million and loss per share to US$1.99, highlighting a tension between short-term quarterly progress and heavier year-to-date spending. We’ll now consider how this quarterly... | ||
 Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates Xencor (XNCR) delivered earnings and revenue surprises of +64.63% and +337.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
Sector Update: Healthcare Stocks Decline Late Afternoon Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 1.5% and | MMT Newswires | |
 Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock? Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. | ||
Sector Update: Healthcare Stocks Mixed Late Afternoon Healthcare stocks were mixed late Friday afternoon, with the NYSE Healthcare Index unchanged and the | MMT Newswires | |
EExec Edge | ||